Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 Inhibitor Maintenance Therapy After Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma
NCT06964568Phase 3Recruiting
- Sponsor
- Fudan University
- Start
- Feb 2025
- Primary completion
- Feb 2029
- Countries
- 1
01
Overview
Phase 3, randomised trial in Esophageal Squamous Cell Carcinoma (ESCC) (4 arms), sponsored by Fudan University. Primary endpoint: Progression-Free Survival at 2 years. Started Feb 2025; status: recruiting.
02
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06964568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06964568.